Bottom line
Is ETIHX a good fund? The bottom line
ETIHX is a share class of Eventide Healthcare & Life Sciences Fund, an actively managed health care sector mutual fund from Mutual.
Its expense ratio is 1.29% — about $129 a year on every $10,000 invested, more expensive than 73% of health care sector funds we track.
It returned +56.7% over one year, +1.0% a year over five years, +10.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.8 billion in net assets and 93 holdings, its largest position is Guardant Health Inc (5.4%) and the top 10 make up 32.4% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.29%)
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What ETIHX invests in
The Eventide Healthcare & Life Sciences Fund (the Healthcare & Life Sciences Fund or the Fund) seeks to achieve long-term capital appreciation.
Under normal market conditions, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies may include private and other companies whose securities may have legal or contractual restrictions on resale or are…
From the fund's prospectus (filed Oct 28, 2026).
ETIHX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ETIHX | +56.7% | +1.0% | +10.8% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What ETIHX costs
On a $10,000 investment, ETIHX's 1.29% expense ratio costs about $129 a year. The prospectus estimates $1,556 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
ETIHX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Guardant Health Inc | 5.37% |
| 2 | US Bank Mmda | 3.75% |
| 3 | Mirum Pharmaceuticals Inc | 3.47% |
| 4 | Kymera Therapeutics Inc | 3.22% |
| 5 | Abivax Sa | 2.94% |
| 6 | BeLite Bio Inc | 2.83% |
| 7 | Trevi Therapeutics Inc | 2.77% |
| 8 | Mbx Biosciences Inc | 2.70% |
| 9 | Vaxcyte Inc | 2.69% |
| 10 | Cytokinetics Inc | 2.69% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 32.4% of the fund. See all top 25 holdings and asset mix →